Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids.

Autor: Wang GS; University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Department of Pediatrics, 13123 East 16th Ave B251, Aurora, CO 80045, United States of America. Electronic address: george.wang@childrenscolorado.org., Buttorff C; RAND Corporation, United States of America. Electronic address: buttorff@rand.org., Wilks A; RAND Corporation, United States of America. Electronic address: awilks@rand.org., Schwam D; RAND Corporation, United States of America. Electronic address: dschwam@rand.org., Tung GJ; University of Colorado Anschutz Medical Campus, Colorado School of Public Health, Department of Health Systems, Management & Policy, United States of America. Electronic address: Gregory.tung@cuanschutz.edu., Banerji S; Rocky Mountain Poison and Drug Safety, Denver Health Hospital AuthorityShireen, United States of America. Electronic address: Shireen.banerji@rmpds.org., Dart RC; Rocky Mountain Poison and Drug Safety, Denver Health Hospital AuthorityShireen, United States of America., Pacula RL; University of Southern California, Sol Price School of Public Policy, Schaeffer Center for Health Policy & Economics, United States of America. Electronic address: Rmp_302@usc.edu.
Jazyk: angličtina
Zdroj: The American journal of emergency medicine [Am J Emerg Med] 2022 Mar; Vol. 53, pp. 150-153. Date of Electronic Publication: 2022 Jan 11.
DOI: 10.1016/j.ajem.2022.01.004
Abstrakt: Introduction: Over the past 10 years, opioids and cannabis have garnered significant attention due to misuse and legalization trends. Different datasets and surveillance mechanisms can lead to different conclusions the due to a variety of factors. The primary objective of this study was to compare and describe trends of opioid, cannabis, and synthetic cannabinoid-related healthcare encounters and poison center (PC) cases in Colorado, a state that has legalized cannabis.
Methods: This was a retrospective study comparing hospital claims data (Colorado Hospital Association (CHA)) and poison center cases to describe opioid, cannabis and synthetic cannabinoid-related healthcare encounters and exposures in Colorado from 2013 to 2017 using related genetic codes and International Statistical Classification of Disease codes.
Results: Both datasets observed increases in cannabis related encounters and exposures after recreational cannabis legalization in 2014. CHA reported an increase for cannabis-related ER visits from 14,109 in 2013 to 18,118 in 2017 while PC noted a 74.4% increase in cannabis-related cases (125 to 218). CHA inpatient visits associated with cannabis also increased (8311 in 2013 to 14,659 in 2017). On the other hand, Opioid-related exposures to the PC fell (1092 in 2013 to 971 in 2017) while both Opioid-related ER visits (8580 in 2013 to 12,928 in 2017) and inpatient visits in CHA increased (9084 in 2013 to 13,205).
Conclusions: This study demonstrates the differences in surveillance methodology for concurrent drug abuse epidemics using hospital claims and PC data. Both systems provide incomplete reports, but in combination can provide a more complete picture.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: